GlassScriptPhysician profile
Shirley J Budding
NPI 1982650750
$8,638.66
in general payments reported to CMS, 2019-2025
23 companies · $2,513 in 2025
The $2,513 reported for 2025 was more than what 94% of Psychiatric/Mental Health, Adult (Clinical Nurse Specialist) providers received nationally (typical 2025 total: $174).
See the full distribution for Psychiatric/Mental Health, Adult (Clinical Nurse Specialist)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $371 · 2022: $669 · 2023: $1,954 · 2024: $3,133 · 2025: $2,513.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,587 · Education: $12.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,587.42 |
| Education | $12.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $1,874.75 | 2021-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Abbvie INC. | $969.34 | 2022-2025 | |
| Axsome Therapeutics, INC. | $958.95 | 2023-2025 | Auvelity, Sunosi |
| Janssen Pharmaceuticals, INC | $791.16 | 2021-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Otsuka America Pharmaceutical, INC. | $696.34 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Alkermes, INC. | $564.05 | 2021-2025 | Aristada, Lybalvi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $549.69 | 2021-2025 | Caplyta |
| E.R. Squibb & Sons, L.L.C. | $476.54 | 2024-2025 | Cobenfy |
| Vanda Pharmaceuticals INC. | $393.53 | 2024-2025 | Fanapt, Hetlioz |
| Neurocrine Biosciences, INC. | $236.92 | 2022-2025 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $224.83 | 2023-2025 | Trintellix |
| Idorsia Pharmaceuticals US INC | $219.33 | 2023-2024 | Quviviq |
| Lundbeck LLC | $191.39 | 2023-2025 | Rexulti, Abilify Maintena |
| Noven Therapeutics, LLC | $133.31 | 2023-2025 | Xelstrym |
| Janssen Scientific Affairs, LLC | $102.45 | 2024 | Spravato, Invega Trinza |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $55.82 | 2023-2025 | Dyanavel Xr |
| Corium, LLC | $54.03 | 2023-2024 | Azstarys |
| Biogen, INC. | $39.20 | 2025 | Zurzuvae |
| Sunovion Pharmaceuticals INC. | $24.74 | 2022 | |
| Ironshore Pharmaceuticals INC. | $24.57 | 2023 | Jornay Pm |
| Janssen Biotech, INC. | $24.04 | 2025 | Tremfya |
| Supernus Pharmaceuticals, INC. | $19.83 | 2022 | |
| Tempus Ai, INC | $13.85 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shirley Budding listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.